For Immediate Release
Chicago, IL – March 11, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: UnitedHealth Group Incorporated (
UNH Quick Quote UNH - Free Report) , Pfizer Inc. ( PFE Quick Quote PFE - Free Report) , International Business Machines Corporation ( IBM Quick Quote IBM - Free Report) , Humana Inc. ( HUM Quick Quote HUM - Free Report) and Exelon Corporation ( EXC Quick Quote EXC - Free Report) . Here are highlights from Wednesday’s Analyst Blog: Top Analyst Reports for UnitedHealth, Pfizer and IBM
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group, Pfizer and International Business Machines. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>> UnitedHealth shares have outperformed the Zacks Medical Insurance industry over the past year (+26.7% vs. +17.2%). The Zacks analyst believes that the company remains well poised to gain from its government business, comprising both Medicaid and Medicare Advantage.
The company’s top line is bolstered by new deals, renewed agreements and expansion of service offerings. Its numerous acquisitions bode well for its inorganic growth profile. The company’s solid health services segment provides significant diversification benefits.
A sturdy balance sheet and consistent cash flow generation is another positive, which has resulted in a solid capital position. This has empowered the company to engage in share buybacks and dividend payments programs. However, it is witnessing a slowdown in international and commercial business.
) read the full research report on UnitedHealth here >>>
Pfizer have lost -4.5% in the last six months against the Zacks Large-Cap Pharmaceuticals industry’s gain of +2.1%. The Zacks analyst believes that strong growth of key brands like Ibrance, Inlyta and Eliquis is likely to drive sales for the company.
Its COVID-19 vaccine candidate, developed in record time, is now approved for emergency use in several countries. Pfizer boasts a sustainable pipeline with multiple late-stage pipeline programs that can drive growth.
However, currency headwinds and pricing pressure are key top-line headwinds. Meanwhile, its Upjohn unit was a cash rich business and its divestiture will reduce the company’s cash flow.
) read the full research report on Pfizer here >>> IBM shares have gained +1.5% over the past three months against the S&P 500’s gain of +6.2%. The Zacks analyst believes that the company is poised to gain from spin-off of legacy infrastructure services business as it focuses on its hybrid cloud strategy.
Strong patent portfolio and solid uptake of IBM’s cloud-based solutions, blockchain, security, and digital transformation offerings also bode well. Furthermore, synergies from Red Hat buyout are strengthening its competitive position in the hybrid cloud market.
Moreover, intense competition in the cloud computing market from Amazon Web Services and Microsoft Azure remains a major headwind. Additionally, higher current debt levels amid extensive restructuring activities are other concerns.
) read the full research report on IBM here >>>
Other noteworthy reports we are featuring today include Humana and Exelon.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.